2026-06-24 from ctvnews.ca

Health Canada has approved Zepbound (tirzepatide) as the first medication in Canada indicated for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults living with obesity.

The approval marks a new development in the treatment of a condition that affects breathing during sleep and can contribute to a range of health complications, including cardiovascular disease, Type 2 diabetes and daytime fatigue. OSA occurs when the upper airway becomes blocked during sleep, causing repeated interruptions in breathing throughout the night. 

Read more here